Intended for professional aesthetic use in line with local regulations governing PLLA biostimulatory injectables.
Detailed information on device classification, registration and conformity is provided in the iLLUMA PLLA brochure and technical documentation available from the distributor.
Intended for professional aesthetic use in line with local regulations governing PLLA biostimulatory injectables.
Detailed information on device classification, registration and conformity is provided in the iLLUMA PLLA brochure and technical documentation available from the distributor.
iLLUMA PLLA 500 is a poly-L-lactic acid (PLLA) collagen-stimulating injectable designed to promote tissue regeneration and long-lasting, natural volumisation with minimal product application. The formulation is based on PLLA particles that stimulate fibroblasts to produce new collagen over time, improving skin texture, elasticity and firmness. A consistent particle shape supports smooth reconstitution and injection, helping to minimise needle clogging and ensuring even distribution in the tissue. Used by trained professionals, iLLUMA PLLA 500 provides gradual, natural-looking volume restoration while simultaneously enhancing overall skin quality.
Bnefits
Promotes tissue regeneration by stimulating the body’s own collagen production.
Boosts collagen synthesis for firmer, more elastic and resilient skin.
Provides a long-lasting, natural volumising effect that develops gradually over time.
Helps reduce the appearance of wrinkles and improve overall skin texture.
Supports skin hydration and elasticity through collagen remodelling and dermal thickening.
Consistent PLLA particle shape enables smooth reconstitution and injection with reduced risk of needle clogging.
Designed to deliver natural outcomes with subtle, progressive changes rather than abrupt volume changes.
Time-efficient in the long term, as results typically require fewer maintenance sessions once full effect is achieved.
Indications
Volume restoration and contour improvement in areas of age-related volume loss, as determined by the treating practitioner.
Stimulation of collagen production to enhance skin elasticity and firmness.
Improvement of fine lines, wrinkles and skin texture in appropriate facial and body areas.
Treatment plans aimed at long-lasting, natural volumisation rather than short-term filling.
Professional biostimulatory treatment in suitable adult patients, in line with local regulations and clinical protocols.
Poly-L-lactic acid (PLLA) particles as the primary biostimulatory ingredient.
Other excipients and formulation components suitable for injectable PLLA products (full technical list provided in the official iLLUMA PLLA brochure and pack leaflet).
Formulation
PLLA-based biostimulatory injectable supplied for reconstitution prior to use.
Designed to be diluted with an appropriate volume of sterile diluent according to the protocol to achieve the desired suspension for injection.
Intended for deep dermal or subdermal injection using a needle or cannula as per manufacturer and clinic guidelines.
Formulated to provide gradual collagen stimulation and volumisation rather than immediate, transient volume from a gel carrier.
Packaging
Supplied as a single or multiple unit product labelled as iLLUMA PLLA 500 (exact vial count and configuration detailed in the official brochure).
Each unit contains PLLA powder intended for reconstitution to a specified dilution volume.
Outer packaging branded with iLLUMA PLLA, including key claims such as tissue regeneration, collagen stimulation and long-lasting natural volumising effect.
Package documentation (brochure/leaflet) provides guidance on dilution volume, recommended cannula/needle options, number of treatments and expected duration of effect.
Usage
For professional use only; treatment must be carried out by qualified medical or aesthetic practitioners experienced with PLLA biostimulatory injectables.
Review the official iLLUMA PLLA brochure and instructions for use for detailed guidance on reconstitution, dilution volume, injection planes and treatment protocols.
Reconstitute the PLLA powder with the recommended volume of sterile diluent and allow appropriate hydration time, following the manufacturer’s protocol to achieve a homogenous suspension.
Before injection, gently agitate the vial or syringe to ensure even distribution of PLLA particles and minimise the risk of clumping or needle clogging.
Assess the patient’s medical history, treatment goals and anatomical considerations; mark treatment areas as required.
Inject using an appropriate needle or cannula and technique (e.g. fanning, linear threading, depot injections) in the recommended tissue plane, taking care to avoid intravascular injection.
Distribute the product evenly across the treatment area to support uniform collagen stimulation and natural volumisation.
A typical treatment plan involves multiple sessions spaced several weeks apart; the exact number of treatments and intervals should follow the protocol and individual patient needs.
Advise the patient on post-treatment care, which may include massaging treated areas if recommended, avoiding strenuous exercise, excessive heat and sun exposure for a specified period, and monitoring for any adverse events.
Dispose of all used vials, needles, cannulas and syringes in accordance with sharps and clinical waste regulations.
Contraindications
Known hypersensitivity or allergy to poly-L-lactic acid or any other component of the formulation.
Active skin infections, inflammation or dermatological conditions at the intended injection sites.
History of severe keloid or hypertrophic scarring in the treatment area.
Patients with uncontrolled systemic disease, significant autoimmune disorders or coagulation abnormalities unless carefully assessed and cleared by a medical professional.
Pregnancy and breastfeeding, as a precaution due to limited safety data in these populations.
Injection into areas with active implants, foreign bodies or where PLLA use is otherwise contraindicated by clinical guidelines.
Any additional contraindications listed in the official iLLUMA PLLA brochure or local clinical protocols for PLLA-based injectables.
Adverse Effects
Expected injection-related reactions such as redness, swelling, tenderness, bruising and discomfort at injection sites, typically resolving within days.
Transient lumps or nodules in the treated area, particularly if massage or distribution is inadequate; these may require clinical management.
Rare risk of granuloma formation or delayed-onset nodules associated with PLLA products.
Possible asymmetry or irregularities if product distribution is uneven or protocols are not followed.
Risk of infection, vascular compromise or other injection-related complications, which should be managed according to established emergency procedures.
Potential post-inflammatory hyperpigmentation or textural changes, particularly in patients prone to PIH or with higher Fitzpatrick skin types.
Storage Conditions
Store at controlled room temperature within the range specified in the official product documentation.
Keep in original packaging to protect from light, moisture and contamination until reconstitution.
Do not freeze or expose to excessive heat or direct sunlight.
Use reconstituted product within the timeframe recommended in the instructions for use; discard any unused reconstituted product after that period.
Do not use after the expiry date printed on the packaging or if the packaging appears damaged.
Duration
Treatment usually consists of multiple sessions spaced weeks apart (as specified in the official protocol), with results lasting many months to years due to progressive collagen stimulation and remodelling; exact duration depends on individual factors and clinical judgment.
Onset
Initial changes may be subtle as PLLA works gradually; visible improvements in volume, skin texture and elasticity typically become more apparent over several weeks to months as new collagen is formed following each treatment session.
